Diffuse large B-cell lymphoma trials in China

In China 133 Also abroad 346

14 of 133 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Where
Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Langfang, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou
Age
18 years and over
People
300 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07200375
No phaseTaking people
Prospective ctDNA Testing in Large B-Cell Lymphoma
Where
Beijing
Age
18 years and over
People
100
Run by
Peking University People's Hospital
See details and how to joinNCT07878351
No phaseNot yet taking people in China
Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Where
Hangzhou
Age
18 years and over
People
30
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07669194
No phaseTaking people
Glofitamab in Chinese Patients With R/R DLBCL
Where
Beijing
Age
18 years to 80 years
People
20
Run by
Peking Union Medical College Hospital
See details and how to joinNCT06481826
No phaseNot yet taking people in China
Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
Where
Zhengzhou
Age
18 years and over
People
20
Run by
Henan Cancer Hospital
See details and how to joinNCT07472621
No phaseTaking people
Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Where
Fuzhou
Age
18 years to 75 years
People
20
Run by
Ting YANG
See details and how to joinNCT07188077
No phaseTaking people
Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Where
Fuzhou
Age
18 years to 75 years
People
10
Run by
Ting YANG
See details and how to joinNCT07198230
No phaseTaking people
Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
Where
Shanghai
Age
18 years and over
People
300
Run by
Fudan University
See details and how to joinNCT07070648
No phaseTaking people
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
Where
Shanghai
Age
18 years and over
People
400
Run by
Ruijin Hospital
See details and how to joinNCT06779435
No phaseTaking people
PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
Where
Shanghai
Age
18 years and over
People
150
Run by
Ruijin Hospital
See details and how to joinNCT06755775
No phaseTaking people
Real-World Study of DLBCL With Different Genetic Subtypes
Where
Shanghai
Age
18 years and over
People
10,000
Run by
Ruijin Hospital
See details and how to joinNCT06026488
No phaseNot yet taking people in China
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
Where
Shanghai
Age
18 years and over
People
200
Run by
Ruijin Hospital
See details and how to joinNCT06656234
No phaseTaking people
Frontline of ASCT in High-risk DLBCL
Where
Beijing
Age
18 years to 70 years
People
175
Run by
Peking University People's Hospital
See details and how to joinNCT05831865
No phaseEnrolling by invitation
Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL
Where
Beijing
Age
18 years to 80 years
People
407
Run by
Chinese Academy of Medical Sciences
See details and how to joinNCT04491721